Jason Meyer, PhD
Associate Professor of Biology, School of Science
Dr. Meyer received his bachelor’s degree from Colgate University and his doctoral degree from the University of Missouri. He completed his postdoctoral training at the University of Wisconsin and was later promoted to the rank of assistant scientist, where he developed the foundational ability to differentiate human pluripotent stem cells into retinal neurons. Since August of 2010, Dr. Meyer has established his research program at IUPUI focused upon the mechanisms underlying the specification and maturation of individual cell types of the retina, with a particular focus upon photoreceptors and retinal ganglion cells. Additionally, Dr. Meyer’s research group is interested in the ability to study features of retinal disease through the use of patient-specific stem cells.
1. Ohlemacher SK, Sridhar A, Xiao Y, Hochstetler A, Sarfarazi M, Cummins TR, and Meyer JS (2016), Stepwise Differentiation of Retinal Ganglion Cells from Human Pluripotent Stem Cells Facilitates Analysis of Glaucomatous Neurodegeneration, Stem Cells,doi: 10.1002/stem.2356. [Epub ahead of print].
2. Sridhar A, Ohlemacher SK, Langer KB, and Meyer JS (2016), Robust Differentiation of mRNA-Reprogrammed Human Induced Pluripotent Stem Cells to a Retinal Lineage, Stem Cells Trans Med, 5(4):417-426.
3. Cooke JA and Meyer JS (2015), Human Pluripotent Stem Cell-Derived Retinal Ganglion Cells: Applications for the Study and Treatment of Optic Neuropathies, Curr Ophthal Reports, 3(3): 200-6.
4. Ohlemacher SK, Iglesias CL, Sridhar A, and Meyer JS (2015), Generation of Highly Enriched Populations of Optic Vesicle-Like Retinal Cells from Human Pluripotent Stem Cells, Curr Prot Stem Cell Biol, .2;32:1H.8.1-1H.8.20.
5. Capowski EE, Simonett JM, Clark EM, Wright LS, Howden SE, Wallace KA, Petelinsek AM, Pinilla I, Phillips MJ, Meyer JS, Schneider BL, Thomson JA, and Gamm DM (2014), Loss of MITF expression during human embryonic stem cell differentiation disrupts retinal pigment epithelium development and optic vesicle cell proliferation, Hum Mol Gen 23(23):6332-44.
6. Zhong X, Gutierrez C, Xue T, Hampton C, Vergara MN, Cao LH, Peters A, Park TS, Zambidis ET, Meyer JS, Gamm DM, Yau KW, and Canto-Soler MV (2014), Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs, Nature Comm 5:4047.
7. Cassidy L, Choi M, Meyer J, Chang R, and Seigel GM (2013), Immunoreactivity of pluripotent markers SSEA-5 and L1CAM in human tumors, teratomas, and induced pluripotent stem cells, J Biomarkers, Article ID 960862, doi:10.1155/2013/960862
8. Sridhar A, Steward MM, and Meyer JS (2013), Non-Xenogeneic Growth and Retinal Differentiation of Human Induced Pluripotent Stem Cells, Stem Cells Translational Medicine, 2(4):255-64.
9. Steward MM, Sridhar A, and Meyer JS (2013), Neural Regeneration, Curr Top Microbiol Immunol, 367:163-91.
10. Meyer JS, Howden S, Wallace KA, Verhoeven A, Wright LS, Capowski EE, Pinilla I, Martin JM, Stewart R, Pattnaik B, Thomson JA, and Gamm DM (2011), Optic Vesicle Structures Derived from Human Pluripotent Stem Cells Facilitate a Customized Approach to Retinal Disease Treatment, Stem Cells, 29(8):1206-18.
11. Gamm DM and Meyer JS (2010), Directed Differentiation of Human Induced Pluripotent Stem Cells: A Retina Perspective, Regen Med, 5(3):315-7.
12. Meyer JS, Shearer RL, Capowski E, Wright LS, Wallace KA, McMillan EL, Zhang SC, and Gamm DM (2009), Modeling Early Retinal Development with Human Embryonic and Induced Pluripotent Stem Cells, Proc Natl Acad Sci,106(39): 16698-703.
13. Wright LS*, Meyer JS*, Capowski EE, and Gamm DM (2009), Derivation and characterization of human retinal progenitor cells, within Stem Cell Transplantation to the Retina: Development, Plasticity, Regeneration and Repair, Ed. by D. Sakaguchi, H. Klassen, and M. Young.
14. Meyer JS, Tullis GT, Pierret CK, and Kirk MD (2009), Detection of Calcium Transients in Embryonic Stem Cells and Their Differentiated Progeny, Cell Mol Neurobiol, Cell Mol Neurobiol, 29(8):1191-203.
15. Gamm D, Wright LS, Capowski EE, Shearer RL, Meyer JS, Kim HJ, Schneider B, Melvan JN, and Svendsen CN (2008), Regulation of Prenatal Human Retinal Neurosphere Growth and Cell Fate Potential by Retinal Pigment Epithelium and Mash1, Stem Cells 26(12): 3182-93.
16. Zhang ZJ, Meyer JS, and Zhang SC (2007), hES differentiation: Neural cell lineages, within Human Embryonic Stem Cells, Ed. by J. Masters, B. Palsson, and J. Thomson.
17. Meyer JS, Katz ML, Maruniak JA, and Kirk MD (2006), Embryonic stem cell derived neural precursors incorporate into the degenerating retina and enhance survival of host photoreceptors, Stem Cells 24(2): 274-283.
18. Meyer JS, Katz ML, and Kirk MD (2005), Stem Cells for Retinal Degenerative Disorders, Ann NY Acad Sci 1049:135-145.
19. Meyer JS, Katz ML, Maruniak JA, and Kirk MD (2004), Neural differenation of mouse embryonic stem cells in vitro and after transplantation into eyes of mutant mice with rapid retinal degeneration, Brain Res 1014(1):131-144.
20. Kirk MD, Meyer JS, Miller MW, and Govind CK (2001), Dichotomy in Phasic-Tonic Neuromuscular Structure of Crayfish Inhibitory Axons, J Comp Neurol 435: 283-90.
Titles & Appointments
- Adjunct Associate Professor of Medical & Molecular Genetics
- Adjunct Associate Professor of Ophthalmology
Induced pluripotent stem (iPS) cells are derived through the genetic reprogramming of somatic cells to yield a population of stem cells capable of giving rise to all cell types of the body. As such, they can be utilized to study some of the earliest events underlying the generationof specific cell types of the nervous system. Current research in the lab focuses upon the differentiation of iPS cells into retinal neurons, with important implications for the study of blinding neurodegenerative diseases. Through the derivation of iPS cells from the somatic cells of patients with known genetic mutations underlying neurodegenerative diseases, it is possible to study the onset and progression of these diseases in the particular cell types affected by the disorder. Such an approach also allows for the development of personalized medicine approaches to treating diseases, as well as pharmacological screening with the goal of identifying novel compounds capable of treating these diseases.